HRT risk is a developing story, confounded by different
Breast cancer risk - calculated variations in absolute risk based on metadata analysis
| Age at calculation | % risk with no HRT | 3 years combination HRT | 5 years combination HRT | 10 years combination HRT | 15 years combination HRT | 3 years oestrogen only HRT | 5 years oestrogen only HRT | 10 years oestrogen only HRT | 15 years oestrogen only HRT |
| 40 | 7.21 | 7.39 | 7.59 | 8.39 | 9.43 | 7.26 | 7.33 | 7.55 | 7.85 |
| 45 | 6.76 | 7.02 | 7.28 | 8.21 | 9.3 | 6.83 | 6.91 | 7.17 | 7.49 |
| 50 | 6.1 | 6.41 | 6.7 | 7.69 | 8.92 | 6.19 | 6.28 | 6.55 | 6.91 |
| 55 | 5.3 | 5.63 | 5.94 | 7.06 | 8.47 | 5.39 | 5.49 | 5.8 | 6.21 |
| 60 | 4.44 | 4.81 | 5.17 | 6.45 | 7.95 | 4.54 | 4.65 | 5.01 | 5.44 |
| 65 | 3.48 | 3.9 | 4.32 | 5.67 | 6.75 | 3.6 | 3.73 | 4.1 | 4.39 |
| 70 | 2.37 | 2.84 | 3.25 | 4.21 | 2.5 | 2.62 | 2.87 | ||
| 75 | 1.14 | 1.57 | 1.72 | 1.26 | 1.28 |
Hormone replacement therapy and breast cancer: estimate of risk
(2005)
Hormone
therapy for menopausal symptoms (2012): the increased risk of breast cancer
associated with use of combined oestrogen-progestogen (hazard ratio 1.24) is
similar to risks conferred by delayed menopause or moderate use of alcohol.
Estimated benefits and risks of oral HRT in postmenopausal women aged 50-59 years, or <10 years after menopause (2012)



Hormone
replacement therapy (2012)